“HER2 Breast Cancer Talk”: A Review of Data from the SABCS 2020 Virtual Symposium - Episode 2

Prognostic Tools for Early-Stage HER2+ Breast Cancer

January 25, 2021

Ruth O'Regan, MD, University of Rochester Medical Center, Joyce O'Shaugnessy, MD, Texas Oncology, Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center, Debu Tripathy, MD, MD Anderson Cancer Center

EP. 1: Current Treatment Landscape for HER2+ Breast Cancer

Now Viewing

EP. 2: Prognostic Tools for Early-Stage HER2+ Breast Cancer

EP. 3: Updated Data for Metastatic HER2+ Breast Cancer

A review of data presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) examining the development and validation of prognostic tools for early stage HER2+ breast cancer.

Data from the following clinical trials are discussed:

First results from a phase 3 randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1–3 positive nodes, hormone receptor–positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPONDER) (Kalinsky K, et al. 2020 SABCS. Poster GS3-00).
Primary outcome results from the WSG-ADAPT HR+/HER2- trial: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0–3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy (Harbeck N., et al. 2020 SABCS. Poster GS4-04).
Continued efficacy of neratinib in patients with HER2-positive early stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial (Holmes FA, et al. 2020 SABCS. Poster PD3-03).
Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early stage breast cancer (Ruiz-Borrego M, et al. 2020 SABCS. Poster PS13-20).
The DAPHNe trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer (Waks AG, et al. 2020 SABCS. Poster PD3-05).
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: Analysis from the ALTTO (BIG 2-06) trial (Lambertini M, et al. 2020 SABCS. Poster PD3-04).

Prognostic Tools for Early-Stage HER2+ Breast Cancer

Data from the following clinical trials are discussed:

Primary outcome results from the WSG-ADAPT HR+/HER2- trial: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0–3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy (Harbeck N., et al. 2020 SABCS. Poster GS4-04).

Continued efficacy of neratinib in patients with HER2-positive early stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial (Holmes FA, et al. 2020 SABCS. Poster PD3-03).

Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early stage breast cancer (Ruiz-Borrego M, et al. 2020 SABCS. Poster PS13-20).

The DAPHNe trial: A feasibility study of chemotherapy de-escalation based on response to neoadjuvant paclitaxel-HP (THP) in HER2-positive breast cancer (Waks AG, et al. 2020 SABCS. Poster PD3-05).

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: Analysis from the ALTTO (BIG 2-06) trial (Lambertini M, et al. 2020 SABCS. Poster PD3-04).